A phase I study of cancer vaccine with NY-ESO-1 overlapping peptides in patients with advanced cancers expressing NY-ESO-1 antigen.

Trial Profile

A phase I study of cancer vaccine with NY-ESO-1 overlapping peptides in patients with advanced cancers expressing NY-ESO-1 antigen.

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Oct 2016

At a glance

  • Drugs Cancer vaccine NY-ESO-1 (Primary) ; Montanide ISA-51; Picibanil
  • Indications Cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 07 Apr 2013 Planned End Date changed from 1 Sep 2011 to 1 Sep 2014 as reported by University Hospital Medical Information Network - Japan.
    • 09 May 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top